Yahoo
OTC Markets OTCPK - Delayed Quote USD

Tetra Bio-Pharma Inc. (TBPMQ)

0.0002 0.0000 (0.00%)
At close: November 4 at 4:00:00 PM EST
Chart Range Bar
Loading chart for TBPMQ
  • Previous Close 0.0002
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 0.0002
  • Volume 850
  • Avg. Volume 0
  • Market Cap (intraday) 84,672
  • Beta (5Y Monthly) 33.46
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0600
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; and REBORN for the treatment of breakthrough cancer pain. It also develops novel prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acute Respiratory Distress Syndrome, sepsis and ophthalmic disease. The company is headquartered in Orléans, Canada.

www.tetrabiopharma.com

33

Full Time Employees

November 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/5/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TBPMQ
0.00%
S&P 500 (^GSPC)
7.42%

1-Year Return

TBPMQ
0.00%
S&P 500 (^GSPC)
8.20%

3-Year Return

TBPMQ
75.00%
S&P 500 (^GSPC)
68.73%

5-Year Return

TBPMQ
99.89%
S&P 500 (^GSPC)
56.54%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY18
Revenue --
Earnings -2.95M
Profit Margin 0.00%

Q2

FY18

-2M
-1M
0
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -38.52%

  • Return on Equity (ttm)

    -315.85%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -39.02M

  • Diluted EPS (ttm)

    -0.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    483.2k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.52M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: